DGAP-News: American Medical Technologies obtains new data on proprietary technology for the early detection of cancer from blood smears
(firmenpresse) - American Medical Technologies (North American) Ltd. / Miscellaneous
19.03.2010 09:30
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
American Medical Technologies obtains new data on proprietary technology
for the early detection of cancer from blood smears
Manalapan, New Jersey | March 18, 2010 | American Medical Technology, Inc.
(AMT, M20 Frankfurt Exchange) today announced that it has received new
results on the efficacy of its proprietary methodology intended for the
early detection of cancer and the evaluation of patient
carcinogenic-resistance using image recognition technology to analyze blood
smears.
AMT's patent pending Blood Cell Morphometric Method TM (BCMM) is the result
of 25 years of research, including historical data for hundreds of
patients, that features several competitive advantages over currently
available diagnostic tests. Competitive advantages include the ability to
detect both the presence of cancerous disease and its location (e.g., lung
cancer, stomach cancer, ovarian cancer, etc.), and the ability to evaluate
a patient's anti-carcinogenic resistance, for use in selecting and
assessing treatment protocols. BCMM is minimally invasive, subjecting
patients only to the drawing of small samples of arterial and venous blood,
and can be utilized before the onset of symptoms or the outbreak of visible
lesions. AMT's BCMM methodology is designed to provide results within hours
of testing. Data from recent clinical applications of BCMM demonstrates a
high degree of accuracy in the early detection of cancer.
Management believes that the early use of its BCMM methodology may produce
valuable data for the fight against cancer and become a significant
participant in the $5.2 billion market worldwide for in vitro cancer
diagnostic tests. The application of BCMM may even impact across the
spectrum of available cancer treatments, a market which has been estimated
to represent $219.2 billion in annual costs.
About American Medical Technologies, Inc.
American Medical Technologies is in the process of developing its patented
Blood Cell Morphometric Method TM (BCMM) methodology in order to
commercialize safe and effective methods for the early diagnosis of cancer.
AMT is committed to changing the practice of medicine by helping millions
of people around the world in the fight against cancer, kidney disease,
rheumatoid arthritis and other serious illnesses by advancing science in a
way that will dramatically improve people's lives. Please visit AMT at
www.americanmedtec.com to learn more about our pioneering
science and innovative company.
Please contact our offices at 1-800-239-5AMT (5268) or email
investor(at)americanmedtec.com
19.03.2010 09:30 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Datum: 19.03.2010 - 09:30 Uhr
Sprache: Deutsch
News-ID 17740
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 304 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: American Medical Technologies obtains new data on proprietary technology for the early detection of cancer from blood smears"
steht unter der journalistisch-redaktionellen Verantwortung von
American Medical Technologies (North American) Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
